Clinical trial · Interventional
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
SBRT With Immunotherapy for Mesothelioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving stereotactic body radiation therapy and immunotherapy may improve the tumors response to the treatment and decrease side-effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pleural Mesothelial Neoplasm | Pleural Mesothelial Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy | Other | — | UNRESOLVED |
| Quality-of-Life Assessment | Other | — | UNRESOLVED |
| Stereotactic Body Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (SBRT, immunotherapy)
- description
- Patients undergo 3-5 daily fractions of SBRT in the absence of disease progression or unacceptable toxicity. Patients also receive immunotherapy at the discretion of the treating medical oncologist.
- interventionNames
- Other: Immunotherapy
- Other: Quality-of-Life Assessment
- Radiation: Stereotactic Body Radiation Therapy
Primary outcomes (1)
- measure
- Feasibility of treating patients with stereotactic body radiation therapy (SBRT) and immune checkpoint inhibitor
- timeFrame
- Up to 2 years
- description
- Feasibility of treating patients with SBRT and ICI will be determined by ability to treat all enrolled patients without meeting stopping rules (maintaining \<30%toxicity).
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>= 18 years * Histological confirmation of pleural mesothelioma * Measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\< 2 * Negative pregnancy test done =\< 14 days prior to registration, for women of childbearing potential only. NOTE: male/female: Must be willing to use birth control for the entire study and must agree to use one of the following birth control methods listed: * Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants * Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) * Intrauterine device (IUD) * Abstinence (no sex) * Provide written informed consent * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * Willing to provide blood samples for correlative research purposes * Patient has received or is planning to receive ICI for mesothelioma * Patient is planning to receive SBRT (stereotactic body radiation therapy) for mesothelioma Exclusion Criteria: * Any of the following: * Pregnant women * Nursing women
References
Publications (0)
Data not yet available